NAD+

Plain-English version: NAD+ is a small helper molecule (a coenzyme) that your cells cannot function without. Every time your body converts food into usable energy, NAD+ is in the middle of the reaction, shuttling electrons. It exists as a pair — NAD+ (the "empty," oxidized form) and NADH (the "loaded," reduced form) — and cells constantly cycle between the two to keep energy production running.

Chemically, NAD+ is a dinucleotide: two nucleotides joined at their phosphate groups, one carrying an adenine base and the other carrying nicotinamide (a form of vitamin B3). Beyond its role in energy metabolism, NAD+ is also consumed as a substrate by three enzyme families that matter enormously for aging: sirtuins (SIRT1-7), which help regulate gene expression, metabolism, and stress resistance; PARPs, which repair damaged DNA; and CD38, an immune-related enzyme. Because these enzymes burn NAD+ to do their jobs, heavy demand — from inflammation, DNA damage, or aging — can drain the cellular pool.^[1][2]

That age-related decline is the premise behind the whole field. You will frequently read that NAD+ drops by "about 50% between ages 40 and 60." Treat that as a directional statement, not a hard fact: it comes from limited, tissue-specific human measurements summarized in review articles rather than from a single large human cohort, and the exact percentage varies by tissue and method.^[1][2] What is well established is that NAD+ availability falls with age and that this decline is mechanistically linked to sirtuin, PARP, and CD38 biology.

The credibility caveat, stated up front: there is a critical difference between the molecule and the products sold to raise it. Oral precursors — nicotinamide riboside (NR, sold as Niagen) and nicotinamide mononucleotide (NMN) — are the forms that have actually been tested in randomized human trials. Injectable and IV NAD+ (the "NAD+ drip") are used off-label in clinics and sold as research chemicals, but they rest on a single small human pharmacokinetic pilot and no efficacy trials.^[11] None of these — NAD+, NMN, or NR — is FDA-approved to treat any condition. For the broader legal picture, see Are Peptides Legal?

Takeaway first: NAD+ is not a drug that flips one switch. It is the raw material several repair-and-maintenance systems depend on. When it runs low, those systems slow down; when it is restored (in animals, at least), several of them speed back up. Here is what the biochemistry actually shows.

1. Redox and energy metabolism

NAD+ is the electron carrier at the heart of the citric-acid (Krebs) cycle and oxidative phosphorylation — the reactions inside mitochondria that produce the bulk of your cellular ATP (energy). NAD+ picks up electrons (becoming NADH) and delivers them to the electron transport chain. When the NAD+/NADH balance shifts with age, mitochondrial energy output falls and reactive oxygen species (cellular "exhaust") can rise. This is textbook, well-established biochemistry.^[1]

2. Sirtuin activation (best-characterized aging link)

Sirtuins are a family of seven enzymes (SIRT1-7), sometimes called "longevity genes," that regulate DNA repair, inflammation, fat and glucose metabolism, and mitochondrial function. Here is the key point: every sirtuin requires NAD+ as a co-substrate. No NAD+, no sirtuin activity — regardless of how much sirtuin protein a cell contains. So when NAD+ declines with age, sirtuin-driven maintenance declines with it. This NAD+-sirtuin dependency is the mechanistic backbone of the longevity argument.^[2]

3. DNA repair via PARPs

Your cells sustain constant DNA damage. PARP enzymes (chiefly PARP1) detect that damage and consume NAD+ to tag it for repair. Under heavy genotoxic stress, PARP activation can dramatically deplete NAD+ — which sets up a competition between DNA repair (PARP) and cellular housekeeping (sirtuins) for a shrinking NAD+ supply. Reviewers describe this PARP-versus-sirtuin tug-of-war as a central feature of NAD+ biology in aging.^[2] In DNA-repair-deficient animal models, restoring NAD+ improved DNA-damage responses and reduced pathology — strong mechanistic support, but in mice and worms, not people.^[12][13]

4. CD38 and the age-related "NAD+ drain"

CD38 is an NAD+-consuming enzyme that increases with age and inflammation. Its rise is one proposed reason NAD+ falls over time — more of the molecule is being burned by CD38 even as production slows. This is part of why simply "topping up" NAD+ is more complicated than it sounds: consumption, not just supply, drives the decline.^[1]

The injectable-NAD+ reality check

Here is where honesty matters most. Most of the mechanism above is established for NAD+ inside the cell. But NAD+ is a large, charged molecule that does not freely cross cell membranes, which raises a real question about how much injected or infused NAD+ actually reaches cells intact versus being broken down first into precursors. The one human study of IV NAD+ — 8 men given 750 mg over 6 hours — found NAD+ was rapidly cleared from plasma (with no measurable rise for roughly the first two hours), after which metabolites and urinary breakdown products appeared. That pilot characterized how the body handles infused NAD+; it measured no clinical benefit at all.^[11] So the mechanistic story is well developed, but the assumption that an injection or drip delivers that mechanism efficiently in humans is not yet demonstrated.

How to read this section: for each area we give the plain-English claim, the proposed mechanism, the population actually studied, the observed effect, and the limitation. Pay close attention to which form was used — nearly every human result below used oral NMN or NR, while the aging and lifespan headlines come from mice. That distinction is the whole ballgame.

Metabolic health and insulin sensitivity (strongest human signal)

Claim: may improve how muscle responds to insulin. Mechanism: NAD+/sirtuin support of glucose and lipid metabolism. Population: 25 overweight or obese, prediabetic, postmenopausal women in a randomized controlled trial. Effect: 250 mg/day of oral NMN for 10 weeks increased insulin-stimulated glucose disposal (measured by the gold-standard hyperinsulinemic-euglycemic clamp) and increased skeletal-muscle AKT/mTOR insulin signaling versus placebo.^[8] Limitation: small trial, one narrow population, and the benefit showed up on a clamp-measured muscle-specific endpoint — not on everyday markers like fasting glucose or HbA1c. The foundational animal work behind this: NMN restored NAD+ and improved glucose tolerance in diet-induced and aged diabetic mice.^[7] This metabolic angle connects NAD+ to broader anti-aging and metabolic-health research.

Physical function in older adults

Claim: may modestly improve walking capacity in people with vascular disease. Mechanism: improved endothelial and mitochondrial function. Population: 90 patients with peripheral artery disease (PAD) in the NICE randomized trial. Effect: 6 months of oral NR improved 6-minute walk distance by about +17.6 meters versus placebo (+7.0 m with NR vs -10.6 m with placebo); adding resveratrol provided no extra benefit.^[10] Limitation: the effect size is modest and arguably at the edge of clinical meaningfulness, and again this is oral NR, not injectable NAD+.

Raising NAD+ levels safely (the cleanest human result)

Claim: oral precursors reliably raise blood NAD+ and are well-tolerated. Mechanism: NR converts to NAD+ through the cell's salvage pathway. Population: 30 healthy middle-aged and older adults in a crossover RCT. Effect: 1,000 mg/day of oral NR for 6 weeks raised the blood NAD+ metabolome by roughly 40-90% with no serious adverse events.^[9] Limitation: this proves NR does what it claims biochemically and is tolerable — it does not by itself prove a downstream health outcome, and it is NR, not NAD+ injection.

Aging and longevity (compelling — but in animals)

Claim: may rejuvenate aged tissue and extend lifespan. Mechanism: restored mitochondrial function and stem-cell activity via the mitochondrial unfolded-protein response and sirtuins. Population: aged mice. Effect: NAD+ repletion with NR rejuvenated muscle, neural, and melanocyte stem cells and modestly increased lifespan.^[5] Limitation: this is a mouse study. It is genuinely important preclinical work, but there is no human lifespan or "reverse aging" data — do not read the mouse result as a human promise.

Vascular aging (animal)

Claim: may restore blood flow and exercise capacity lost to aging. Mechanism: reactivation of endothelial SIRT1, enhanced by hydrogen sulfide, restoring capillary density. Population: aged mice. Effect: NMN restored capillary density and treadmill endurance toward youthful levels.^[6] Limitation: mouse model; no human vascular-density trial of NAD+ exists. For a complementary vascular/mitochondrial peptide, see SS-31.

Brain health and DNA repair (animal / disease-model)

Claim: may protect neurons and reduce Alzheimer's-type pathology. Mechanism: normalized DNA-damage responses, reduced neuroinflammation, improved mitophagy (clearance of damaged mitochondria). Population: DNA-repair-deficient Alzheimer's mouse models, plus worm/mouse ataxia-telangiectasia models. Effect: NAD+ repletion (via NR) reduced tau pathology and neuroinflammation and improved cognition in the AD model,^[12] and extended lifespan/healthspan via mitophagy and DNA repair in ataxia-telangiectasia models.^[13] Limitation: disease-model animals only — this is mechanistic support, not evidence that NAD+ treats human dementia. For cognition-focused peptides, see semax and cerebrolysin.

The honest bottom line on "benefits"

• Human efficacy = oral precursors. Every positive human trial above used oral NMN or NR. The impressive lifespan and rejuvenation headlines are from mice.
• Injectable/IV NAD+ has no efficacy trials. Its human evidence is a single 8-person pharmacokinetic pilot that measured no health outcomes.^[11]
• Effect sizes in humans are modest where they exist (a muscle-specific insulin measure; ~18 m on a walk test).
• Anecdotes are not data. Reports of "more energy" within days are common but uncontrolled and prone to placebo.

Read this first: the doses with actual human trial support are all oral: NMN around 250 mg/day and NR around 300-1,000 mg/day.^[8][9][10] The injectable and IV figures below circulate in clinics and online but are not validated by efficacy trials — the only human injectable data is a single 750 mg IV infusion given over 6 hours for pharmacokinetic study.^[11] We describe injectable protocols for completeness and harm reduction, not as medical guidance, and not as an endorsement of stepping ahead of the evidence.

Doses by form

Form / route	Commonly used amount	Frequency	Evidence level
Oral NR (Niagen)	300-1,000 mg	Daily	Human RCTs (best-tolerated data)[9]
Oral NMN	250-500 mg	Daily	Human RCT at 250 mg/day[8]
Subcutaneous NAD+ (injection)	50-100 mg (start) up to ~250 mg	Daily to 2-3x weekly	No published efficacy trials
IV NAD+ (clinic drip)	250-750 mg per infusion	1-2x weekly	1 human PK pilot only[11]

Route logic in plain terms: oral precursors are convenient, cheapest, and carry the human data, but they rely on the body's enzymes to convert them to NAD+ over days. Injectable and IV NAD+ aim to deliver the molecule "directly," but as the one human PK study showed, infused NAD+ is cleared and metabolized rapidly rather than simply flooding cells — so "direct" is more marketing than established fact.^[11]

Reconstitution math, with a worked example (injectable NAD+)

Injectable NAD+ ships as a lyophilized (freeze-dried) powder that must be mixed with bacteriostatic water before use. The core formula:

Concentration (mg/mL) = vial amount (mg) ÷ water added (mL)

Worked example: take a 500 mg vial and add 5 mL of bacteriostatic water. That gives 500 ÷ 5 = 100 mg/mL. To draw a 100 mg dose: 100 ÷ 100 = 1.0 mL, which is 100 units on a standard 100-unit insulin syringe (a full syringe). For a gentler 50 mg starting dose, draw 0.5 mL (50 units).

Vial	BAC water	Concentration	50 mg dose	100 mg dose
500 mg	5 mL	100 mg/mL	0.50 mL (50 units)	1.00 mL (100 units)
1,000 mg	10 mL	100 mg/mL	0.50 mL (50 units)	1.00 mL (100 units)
500 mg	10 mL	50 mg/mL	1.00 mL (100 units)	2.00 mL (200 units — split)

An NAD+-specific tip: a more dilute solution (lower mg/mL) noticeably reduces the stinging that subcutaneous NAD+ is notorious for, which is why some users deliberately reconstitute with more water. A faint yellow tint in solution is normal for NAD+ and not a sign of degradation. Check volumes with the peptide calculator and bacteriostatic water calculator, and follow the reconstitution guide for a step-by-step walkthrough.

Timing and cycle length

• Morning is preferred. NAD+ interacts with circadian clock genes and cellular energy pathways, and afternoon or evening dosing is a common cause of the reported insomnia. Most protocols dose in the morning.
• No cycling required. Unlike receptor-targeting peptides that can desensitize, NAD+ and its precursors are metabolic substrates — the body uses them as fuel rather than building tolerance. Oral NMN/NR are typically taken continuously, and levels fall again after stopping, so protocols are designed for ongoing use.^[9]
• Injectable "loading." Clinic protocols sometimes front-load daily injections for a few weeks before dropping to 2-3x weekly. This structure comes from convention, not from any human trial.

None of the above is a recommendation to self-administer an unapproved injectable. For beginners, the oral precursors are where the actual human evidence — and the far lower risk — lives. See the general peptide dosage guide for broader context.

Straight talk: NAD+ is a molecule your body already makes, and the best human safety data — for oral NR — is genuinely reassuring: in a 6-week randomized trial, 1,000 mg/day was well-tolerated with no serious adverse events.^[9] Oral NMN at 250 mg/day was likewise well-tolerated in its trial.^[8] But injectable and IV NAD+ have no controlled human safety trials — only a small pharmacokinetic pilot — so their safety profile rests on clinic experience and reasoning, not evidence.^[11] Most reported problems are tied to the route of administration, not the molecule.

Injectable NAD+ (subcutaneous)

Effect	Frequency	Severity	What to do
Injection-site stinging/burning	Very common	Moderate	Dilute the solution, inject slowly (15-30s), warm to room temp, ice the site first
Injection-site redness	Common	Mild	Resolves in hours; rotate sites
Flushing/warmth	Occasional	Mild	More likely at higher doses; transient
Insomnia/restlessness	Occasional	Mild-Moderate	Dose in the morning only
Nausea, headache	Rare	Mild	Reduce dose; stay hydrated

IV NAD+ infusion

The hallmark of IV NAD+ is that side effects are rate-dependent — chest tightness or pressure, nausea, flushing, sweating, and abdominal cramping appear when the drip runs too fast and typically ease within minutes of slowing it. Standard infusions run 1-3 hours for exactly this reason. IV NAD+ should only be given by an experienced clinic able to adjust the rate in real time.

Oral NMN / NR

The mildest profile by far. Reported effects are uncommon and usually limited to mild GI discomfort (nausea, bloating) at higher doses; trials generally report tolerability comparable to placebo.^[9]

The cancer caveat (precautionary, not proven)

This one deserves a clear, honest framing. There is no clinical evidence that NAD+ supplementation causes or accelerates cancer in humans. However, NAD+ fuels the rapid division of all cells — including cancer cells — and NAMPT, an enzyme in the NAD+ synthesis pathway, is an active cancer-drug target precisely because tumors depend on NAD+. That biology makes supplementation during active cancer a legitimate theoretical concern worth respecting, and reviews flag it as such.^[3] The reasonable, conservative position: avoid NAD+ supplementation during active or recent cancer until it is specifically studied, and involve an oncologist.

Drug interactions and who should be cautious

• Chemotherapy: some agents work by depleting cancer-cell NAD+ (NAMPT inhibitors); supplementing NAD+ could theoretically work against them. Avoid without oncology oversight.
• Active or recent cancer: see the caveat above — generally avoid.
• Pregnancy and breastfeeding: no safety data for supplemental doses — avoid.
• Uncontrolled cardiovascular conditions: the transient hemodynamic effects during IV infusion warrant extra caution and medical supervision.
• Children and teens: youthful NAD+ is naturally high and supplementation is unstudied in this group — not appropriate.

The limitations you must keep in mind

• The good human safety data is for oral NR/NMN — not for injectable or IV NAD+.
• Long-term safety of high-dose injectable NAD+ over years is not established from controlled trials.
• Whether chronically elevated NAD+ has unintended downstream effects remains an open research question.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

"NAD+ supplementation" is really a family of options that reach the same destination by different roads. Choosing well means matching the form to what the evidence actually supports.

Factor	NAD+ (injectable/IV)	NMN (oral)	NR / Niagen (oral)	Niacin (B3)
What it is	The coenzyme itself	Precursor, 1 step to NAD+	Precursor, 2 steps to NAD+	Classic B3, multiple steps
Route	SC injection / IV drip	Capsule or sublingual	Capsule	Oral
Human evidence	1 PK pilot, no efficacy trials[11]	RCT: muscle insulin sensitivity[8]	Best safety data; raises NAD+[9]	Long history; causes flushing
Convenience	Injection or clinic visit	Pill	Pill	Pill
Discomfort	Stinging injection	None	None	Flushing

Bottom line: despite the marketing appeal of "direct" NAD+, the oral precursors NR and NMN carry essentially all of the human trial evidence, cost far less, and are far more convenient. A reasonable, evidence-led approach starts with an oral precursor. Injectable NAD+ is the option furthest ahead of its data. A useful comparison of the two precursors is available in the review literature.^[4]

For the broader longevity landscape, see best peptides for anti-aging, which covers NAD+ alongside epitalon, SS-31, and MOTS-c.

Why this section matters: the regulatory picture differs sharply by form, and so does quality risk. Oral NR is a lawful dietary ingredient; injectable NAD+ is an unregulated research chemical where purity and identity vary between suppliers. Knowing the status — and how to read a Certificate of Analysis (COA) — protects you.

Legal and regulatory status (2026)

• No form of NAD+ is an FDA-approved treatment for aging, metabolic, or neurological disease. Claims otherwise are not supported by approval.
• Injectable/IV NAD+ is not an FDA-approved drug product. It is used off-label and compounded in clinics, and sold elsewhere as a research chemical.
• Oral NR (Niagen) is a legal dietary ingredient (GRAS/NDI-notified).
• Oral NMN has had a contested status: in November 2022 the FDA said NMN was excluded from the dietary-supplement definition because it had been studied as an investigational drug; in September 2025 the FDA reversed course and declared NMN lawful for use in dietary supplements.
• None of these is a controlled substance.

What a credible injectable product should show

• Third-party COA: independent HPLC purity testing (look for ≥98%) plus mass-spectrometry identity confirmation.
• Batch-specific results tied to the exact lot you are buying.
• Endotoxin (LAL) testing — essential for anything intended to be injected.
• Proper form and packaging: lyophilized powder in a sealed, light-protected vial (NAD+ is photosensitive).

Red flags

• No COA, or a COA from the seller rather than an independent lab
• Pre-mixed "ready to use" liquid (shorter shelf life, higher contamination risk)
• Prices far below the market
• Explicit medical or "treats aging/disease" claims — a sign of a non-compliant vendor

Storage

Keep unopened lyophilized vials cold and dark — freezer for long-term, refrigerator for months. NAD+ is light-sensitive, so protect vials from direct light (amber vials or foil). Once reconstituted, refrigerate at 2-8°C and use within about 28 days; avoid repeated freeze-thaw cycles and discard anything cloudy or discolored (a faint yellow tint, however, is normal). Oral NMN/NR: store cool and dry, and check the label — some formulations want refrigeration. See the full peptide storage guide, and for the complete legal picture read Are Peptides Legal?